Você esta aqui:Home > Cannabinoids (antigo) > Cannabinoids in cancer pain
Cannabinoids 2010;5(1):1-3 (January 23, 2010)
Article of the Month
Cannabinoids in cancer pain
Franjo Grotenhermen
nova-Institut, Chemiepark Knapsack, Industriestraße, D-50354 Hürth, Germany, franjo.grotenhermen@nova-institut.de
This article of the month presents results of a clinical study conducted in the UK and Romania, which evaluated the efficacy of a THC:CBD cannabis extract (Sativex®) and a THC cannabis ex-tract in the treatment of 177 patients with cancer pain, who experienced inadequate pain reduction despite intake of opioids [Johnson et al. J Pain Symptom Manage, 2010, in press]. Sativex resulted in a significant improvement of mean pain scores on a primary outcome measure, a Numerical Rating Scale (NRS) from 0 to 10 compared to placebo (improvement of -1.37 versus -0.69), while the THC extract caused a non-significant improvement (-1.01). Conversely, there was a significant improvement in total pain according to the Brief Pain Inventory-Short Form in the THC-group compared to placebo but a non-significant improvement following Sativex.
Keywords
cannabis, THC, cannabidiol, chronic pain, cancer, clinical trial.
Eventos Online 2020
Todas as informações sobre os Eventos IACM Online, incluindo vídeos gratuitos dos webinars com legendas em português, podem ser encontradas aqui.
Conferência 2022
A 12ª Conferência IACM sobre Canabinóides em Medicina será realizada nos dias 20 e 21 de Outubro de 2022 juntamente com o SSCM suíço em Basileia/Suíça.
Members only
Regular members can sign up for the new member area of the IACM to access exclusive content.
You need to become a regular member of the IACM to access the new member area.
IACM on Twitter
Follow us on twitter @IACM_Bulletin where you can send us inquiries and receive updates on research studies and news articles.